Concentration ratio

Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones

Retrieved on: 
Monday, January 8, 2024
Well, RNA, Conference, Science, Wave, Messenger, Research, AAT, Chemistry, Pizzicato, Small RNA, Lung, Weight, Health, Disease, MBA, MD, Mouse, HD, Human, Serum, GSK, Mutation, Genetics, Coronary artery disease, Obesity, Genomics, Concentration ratio, Central nervous system, Patient, Liver disease, Lof, HTT, Medicine, Therapy, Oligonucleotide, NHP, CTA, Vaccine

We expect 2024 will be an inflection year that will drive significant value for Wave, our shareholders, and most importantly, for the patients who will benefit from our research,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.

Key Points: 
  • We expect 2024 will be an inflection year that will drive significant value for Wave, our shareholders, and most importantly, for the patients who will benefit from our research,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.
  • Expected milestones: Wave plans to deliver proof-of-mechanism data in individuals with AATD in 2024.
  • Expected milestones: Wave expects to deliver data, including dystrophin protein expression from muscle biopsies at 24 weeks, in the third quarter of 2024.
  • A live webcast of this presentation will be available on the Investor Relations page of the Wave Life Sciences website at http://ir.wavelifesciences.com .

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Retrieved on: 
Wednesday, January 3, 2024
Other Health, Research, General Health, Cannabis, Pharmaceutical, Mental Health, Natural Resources, Clinical Trials, Science, Biotechnology, Other Science, Health, IND, HTR, Depression, Mouse, Human, Addiction, Anxiety, Hallucination, Artificial intelligence, Concentration ratio, Therapy, DMT, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided an update on data underpinning the selection of EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided an update on data underpinning the selection of EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.
  • 5-HT2A is the key receptor correlated to the neuroplastogenic activity of this emerging class of novel drugs.
  • 5-HT1A is a known important therapeutic target because other, already-approved medications for neuropsychiatric indications are known to bind this receptor.
  • HTR is a rodent behavioral model used to predict whether a molecule is likely to produce hallucinogenic effects in humans.

Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency

Retrieved on: 
Wednesday, December 6, 2023
RNA, Liver, Messenger, AAT, Lung, Pizzicato, Chemistry, RNA editing, Disease, MBA, Aimer, MD, Human, Serum, GSK, Mutation, Biomarker, Concentration ratio, Patient, Liver disease, Therapy, Vaccine

CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of dosing in healthy volunteers in the RestorAATion clinical trial program, which is investigating WVE-006 as a potential treatment for alpha-1 antitrypsin deficiency (AATD).

Key Points: 
  • It is designed to restore circulation of healthy, wild-type alpha-1 antitrypsin (M-AAT) protein and reduce dysfunctional Z-AAT protein, thereby potentially addressing AATD-related lung disease, liver disease, or both.
  • In preclinical studies, WVE-006 led to potent and durable RNA editing and restoration of AAT protein up to 30 micromolar, underscoring the impact of our novel chemistry.
  • Beyond WVE-006, we’re also excited to continue our collaboration with Wave Life Sciences using their best-in-class PRISM™ platform.”
    With initiation of dosing in RestorAATion, Wave has achieved its first WVE-006 milestone in its collaboration with GSK, resulting in a $20 million payment to Wave.
  • Beyond WVE-006, Wave is advancing a pipeline of wholly owned RNA editing therapeutics designed to either correct or upregulate mRNA across a range of high impact targets.

EQS-News: SYNLAB AG: SYNLAB plays key role in the largest ever multinational study on cholesterol

Retrieved on: 
Monday, July 17, 2023
Quest Diagnostics, Triglyceride, Cholesterol, Cardiovascular disease, FSE, University College, Oxford, Research, DASA, GDN, Korea, South Korea, Laboratory, Risk, Concentration ratio, European Heart Journal, LDL, United Kingdom, Strand Life Sciences, WHO, Society, Pharmaceutical industry, Copper

SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, provided significant support for the largest ever multi-national study on circulating cholesterol concentrations.

Key Points: 
  • SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, provided significant support for the largest ever multi-national study on circulating cholesterol concentrations.
  • It posits that geographical location and sex as well as cultural and genetic differences influence cholesterol levels.
  • The research, moreover, includes medically recognised laboratory markers of cardiovascular disease risk, including levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides.
  • Of these, the highest mean total cholesterol levels were in Austria (5.40 mmol/L, 208.8 mg/dL) and Germany (5.35 mmol/L, 206.9 mg/dL).

Analysis of Half a Billion Lipid Tests from Five Continents Reveals Wide Variation of Heart Disease Lipid Risk by Country and Sex

Retrieved on: 
Monday, July 10, 2023
Senior, Prevalence, Public, Johns Hopkins University, MD, Patient, Risk, Concentration ratio, Health, NYSE, DGX, Geography, Quest Diagnostics, Genetics, Cholesterol, Policy, Cardiovascular disease, Research, DASA, Laboratory, LDL, Business, Public policy, MHS, Genetic disorder, South Korea, Consumer, WHO, World Health Organization, Johns Hopkins School of Medicine, FH, HDL, GDN, Korea, European Heart Journal, United Kingdom, Strand Life Sciences, Pharmaceutical industry, Copper, Vaccine, Medical device, Medicine

Published in European Heart Journal , the analysis includes globally recognized laboratory markers of cardiovascular disease risk, including levels of total cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and triglyceride.

Key Points: 
  • Published in European Heart Journal , the analysis includes globally recognized laboratory markers of cardiovascular disease risk, including levels of total cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and triglyceride.
  • The World Health Organization (WHO) and clinical practice guidelines in different countries recognize lipid testing’s clinical value.
  • Of these, the highest mean total cholesterol levels were in Austria (5.40 mmol/L, 208.8 mg/dL) and Germany (5.35 mmol/L, 206.9 mg/dL).
  • While the laboratories involved in the analysis are leaders in their respective countries, their laboratory data may not fully represent any particular country or geography.

Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress

Retrieved on: 
Friday, June 23, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Chloride, ALGS, Maintenance, EASL, Hippeastrum mirum, Cholestasis, SBA, Sleep, Research, Doctor of Philosophy, MRX, Medication, Congress, HIV disease progression rates, Patient, Concentration ratio, Bilirubin, Itch, Progressive familial intrahepatic cholestasis, IBAT, Alagille syndrome, Ageing, European Association for the Study of the Liver, PFIC, Safety, Pharmaceutical industry, Medical imaging, Fertilizer, Surveying, Toy, Liver

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria.
  • The congress presentations feature new analyses from the LIVMARLI® (maralixibat) oral solution MARCH-PFIC study as well as the long-term extension study, MARCH-ON.
  • Additionally, data showing LIVMARLI’s benefit in adult patients with Alagille syndrome (ALGS) was presented during EASL.
  • All presentations are available in the Publications and Presentations section on Mirum’s website.

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023

Retrieved on: 
Thursday, June 15, 2023
ENDO, MVE, CV, Shoulder, Spasm, Fetus, Lactation, Pregnancy, Bempedoic acid, CTT, Pain, Patient, Analysis, Risk, Concentration ratio, The New England Journal of Medicine, Disease, Gout, Diet, Myocardial infarction, Ezetimibe, ANN, Drug, Simvastatin, Pravastatin, Back pain, ESPR, Tablet, Death, Safety, Rotator cuff, Atrial fibrillation, Stroke, CVD, Abdominal pain, Uric acid, Molina Healthcare, Anemia, Mortality, IL, Achilles tendon, Bronchitis, Tendon rupture, ATP, Rupture, Kidney, CLEAR, Moyamoya disease, Upper respiratory tract infection, Health, Pharmaceutical industry, Dietary supplement, Esperies, Hyperuricemia

“We are pleased to present this analysis at ENDO 2023, demonstrating that the cardiovascular risk reduction benefit of bempedoic acid treatment is comparable to that of statins based on an analysis of per unit decrease in LDL-C,” said Sheldon Koenig, President and CEO of Esperion.

Key Points: 
  • “We are pleased to present this analysis at ENDO 2023, demonstrating that the cardiovascular risk reduction benefit of bempedoic acid treatment is comparable to that of statins based on an analysis of per unit decrease in LDL-C,” said Sheldon Koenig, President and CEO of Esperion.
  • The beneficial effect of bempedoic acid on MVE reduction generally improved over time, similar to what was observed in statin CVOTs.
  • Limitations of Use: The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

PIC Therapeutics Presents Pre-Clinical Data Update on eIF4E Regulators at AACR Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023
Oncology, Health, Stem Cells, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, DNA, AACR, Cell death, Aggression, Neoplasm, Cell, Survival, American Association for Cancer Research, CDK, Messenger, Concentration ratio, Patient, Apoptosis, Allosteric regulation, PIC, Poster, Therapy, Factorization of polynomials, Metastasis, ER, Breast cancer, DNA repair, Pharmaceutical industry, Vaccine

PIC compound regulation of eIF4E induces rapid commitment to apoptosis and selective proteomic shifts that are consistent with canonical eIF4E regulation including cell cycle impacts, e.g.

Key Points: 
  • PIC compound regulation of eIF4E induces rapid commitment to apoptosis and selective proteomic shifts that are consistent with canonical eIF4E regulation including cell cycle impacts, e.g.
  • Previous communications revealed our eIF4E regulators potently cause cell death in primary breast cancer organoid models, but spared models derived from healthy tissue.
  • Our eIF4E regulators did not impair survival of these cells up to a maximum tested dose of 25 micromolar.
  • Our eIF4E regulators represent a potential beneficial therapeutic approach to address multiple resistant cancer patient populations and fulfill the promise of this elusive target.

Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, February 21, 2023
Shoulder, Medicaid, Achilles tendon, Pregnancy, Diet, Moyamoya disease, State Administrative Expenses, Atrial fibrillation, MACE, Upper respiratory tract infection, Acceleration, Abdominal pain, PIN, Uric acid, Spasm, Pain, Simvastatin, Medicare, Hosting, Cholesterol, Patient, Pravastatin, Bronchitis, Back pain, Disease, Drug, Anemia, Lactation, Fetus, Sale, Health, Mortality, Cardiology, Gout, Risk, Congress, ESPR, Major adverse cardiovascular events, Treasury, CLEAR, Concentration ratio, Research, Cardiovascular disease, EmblemHealth, Kidney, Rotator cuff, Medical imaging, Pharmaceutical industry, Cryptocurrency, Dietary supplement, Hyperuricemia, Tufts University, Esperies

ANN ARBOR, Mich., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Key Points: 
  • “I’m proud of the entire organization at Esperion and our ability to deliver on the commitments we made in 2022.
  • The increase for the fourth quarter ended December 31, 2022, is related to increases in net U.S. product revenue and royalty revenue.
  • These decreases reflect savings from the transformative plan implemented in the fourth quarter of 2021.
  • Esperion works hard to make our medicines easy to get, easy to take, and easy to have.

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

Retrieved on: 
Wednesday, December 7, 2022
Online, Bronchitis, Moyamoya disease, Atrial fibrillation, Simvastatin, Kidney, Cardiovascular disease, National Center for Health Research, Shoulder, Abdominal pain, Mortality, ANN, Pregnancy, Health, ATP, Security (finance), ESPR, Uric acid, Rotator cuff, Drug, Diet, National Center for Health Statistics, Back pain, Pravastatin, Centers for Disease Control and Prevention, Pain, CDC, World Heart Federation, Spasm, Gout, Cholesterol, Lactation, Fetus, Disease, Upper respiratory tract infection, Achilles tendon, Concentration ratio, GA, Growth, CLEAR, Risk, Medical statistics, COVID-19, Patient, Anemia, Tendon rupture, Pharmaceutical industry, Dietary supplement, Hyperuricemia, Bempedoic acid, Death, Esperies

ANN ARBOR, Mich., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in patients treated with 180 mg/day NEXLETOL compared to placebo.

Key Points: 
  • CLEAR Outcomes further strengthens the clinical evidence supporting the role of bempedoic acid for patients.”
    Cardiovascular disease remains the number one killer globallyi.
  • A large proportion of patients at risk for cardiovascular events based on elevated LDL-cholesterol and apolipoprotein b are not adequately treated with existing therapies.
  • Despite recent therapeutic advances, there remains a significant need for new treatment options to help improve long-term cardiovascular outcomesii.
  • Limitations of Use: The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined.